‘Novavax has submitted an application to the Food and Drug Administration for Emergency Use Authorization of its COVID-19 vaccine as a booster in adults that can be used on top of the its primary vaccine series or to mix and match with a different primary series, the company announced.

"It's important for people to have a choice as they evaluate how to stay protected against COVID-19, and boosters are an invaluable tool to build upon immunity obtained from previous vaccinations," Stanley C. Erck, President and Chief Executive Officer of Novavax, said in a statement on Monday.

"Based on the data presented to the FDA's VRBPAC and the CDC ACIP, we believe our vaccine offers a broad, long-lasting immune response against a range of variants," Erck said.’

[link to abcnews.go.com (secure)]